类风湿关节炎合并癌症病史患者接受bDMARD治疗的癌症复发风险:一项丹麦全国注册队列研究
该丹麦全国注册队列研究纳入720例类风湿关节炎合并六种实体癌缓解期患者,比较bDMARD与csDMARD启动者的癌症复发风险。任何bDMARD、TNFi或利妥昔单抗组的癌症复发风险均未见统计学显著升高,乳腺癌复发亦无升高。
要点
- 任何bDMARD组癌症复发HR 0.92(95%CI 0.38-1.73),与csDMARD组相比无统计学显著差异。
- TNFi组癌症复发HR 1.10(95%CI 0.21-3.16),与csDMARD组相比无统计学显著差异。
- 利妥昔单抗组癌症复发HR 0.94(95%CI 0.32-2.11),与csDMARD组相比无统计学显著差异。
核心结论
- 在类风湿关节炎合并实体癌缓解期患者中,与csDMARD治疗相比,临床实践中使用的bDMARD未见癌症复发风险增加的迹象。
研究设计与样本
- 丹麦全国注册队列研究,纳入720例类风湿关节炎合并六种算法特定实体癌(乳腺癌、结直肠癌、黑色素瘤、膀胱癌、子宫内膜癌和肺癌)缓解期患者。
- bDMARD暴露分为三组:任何bDMARD组170例、TNFi组81例、利妥昔单抗组99例;csDMARD启动者651例。
- 采用逆概率治疗加权和加权病因特异性Cox模型计算癌症复发HR,随访时间2002年至2021年。
主要发现
- 任何bDMARD组癌症复发HR 0.92(95%CI 0.38-1.73),与csDMARD组相比无统计学显著差异。
- TNFi组癌症复发HR 1.10(95%CI 0.21-3.16),与csDMARD组相比无统计学显著差异。
- 利妥昔单抗组癌症复发HR 0.94(95%CI 0.32-2.11),与csDMARD组相比无统计学显著差异。
- 乳腺癌复发风险亦未见升高。
关键数值与推荐
- 任何bDMARD组癌症复发HR 0.92(95%CI 0.38-1.73),与csDMARD组相比。
- TNFi组癌症复发HR 1.10(95%CI 0.21-3.16),与csDMARD组相比。
- 利妥昔单抗组癌症复发HR 0.94(95%CI 0.32-2.11),与csDMARD组相比。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the risk of cancer recurrence in patients with rheumatoid arthritis (RA) and a prior solid cancer in remission treated with biological disease-modifying antirheumatic drugs (bDMARDs) compared with those who received only conventional synthetic DMARDs (csDMARDs). METHODS: Nationwide registry-based cohort study of Danish patients with RA and one of the six algorithm-specific solid cancers in remission (breast, colorectal, melanoma, bladder, endometrial and lung) who initiated treatment with a bDMARD or a csDMARD. Three bDMARD exposure groups were defined according to the type(s) of bDMARD initiated: (1) any bDMARD, (2) tumour necrosis factor inhibitors (TNFi) and (3) rituximab. Patients were identified in Danish Rheumatology Quality Register and followed for cancer recurrence from 2002 to 2021 using validated cancer-specific recurrence algorithms. Inverse probability of treatment weighting and weighted cause-specific Cox models were used to calculate HRs for cancer recurrence in each bDMARD exposure group compared with a csDMARD-treated group. RESULTS: Among 720 unique patients with RA and an algorithm-specific solid cancer in remission, 170 any bDMARD, 81 TNFi, 99 rituximab and 651 csDMARD initiators were identified. No statistically significant increased HRs for cancer recurrence were found with any type of bDMARD 0.92 (95% CI 0.38 to 1.73), TNFi 1.10 (95% CI 0.21 to 3.16) or rituximab 0.94 (95% CI 0.32 to 2.11). Also, no increased HRs were shown for breast cancer recurrence specifically. CONCLUSION: No indications of increased cancer recurrence risk were found for bDMARDs as used in clinical practice in patients with RA and a solid cancer in remission when compared with csDMARD treatment.
引用
- Westermann R, Cordtz R, Duch K, et al. Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study. RMD Open. 2025. PMID: 40254339. doi:10.1136/rmdopen-2024-005247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。